Ascendis Pharma Announces Proposed Public Offering of ADSs

Ascendis Pharma (Nasdaq:ASND), a clinical stage biopharmaceutical company, announced that it has commenced an underwritten public offering of $150,000,000 of American Depositary Shares, each of which represents one ordinary share of Ascendis.

As quoted in the press release:

 The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. J.P. Morgan Securities LLC, BofA Merrill Lynch and Credit Suisse Securities (USA) LLC are acting as joint book-running managers for the offering.

Click here to read the full press release.